Strategic Partners A/S
Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. The company was founded in 2009 and is based in Herlev, Denmark.
Strategic Partners A/S (1TB0) - Net Assets
Latest net assets as of June 2025: €18.06 Million EUR
Based on the latest financial reports, Strategic Partners A/S (1TB0) has net assets worth €18.06 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€18.85 Million) and total liabilities (€789.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €18.06 Million |
| % of Total Assets | 95.81% |
| Annual Growth Rate | 27.25% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.68 |
Strategic Partners A/S - Net Assets Trend (2021–2024)
This chart illustrates how Strategic Partners A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Strategic Partners A/S (2021–2024)
The table below shows the annual net assets of Strategic Partners A/S from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €19.25 Million | +35.15% |
| 2023-12-31 | €14.24 Million | +52.50% |
| 2021-12-31 | €9.34 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Strategic Partners A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 212398900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €12.99 Million | 67.49% |
| Other Components | €6.26 Million | 32.51% |
| Total Equity | €19.25 Million | 100.00% |
Strategic Partners A/S Competitors by Market Cap
The table below lists competitors of Strategic Partners A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SPEQTA AB
F:23WA
|
$1.31 Million |
|
Dogwood Therapeutics, Inc.
NASDAQ:DWTX
|
$1.31 Million |
|
GLACIER LAKE RES
F:KDM
|
$1.31 Million |
|
Dantax
CO:DANT
|
$1.31 Million |
|
Lexston Life Sciences Corp
OTCQB:LEXTF
|
$1.31 Million |
|
RIGHTBRIDGE VENTURES GRP
F:K0B0
|
$1.31 Million |
|
Source Physical Palladium P
XETRA:8PSC
|
$1.31 Million |
|
AS Ekspress Grupp
F:DYC
|
$1.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Strategic Partners A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 14,242,000 to 19,248,000, a change of 5,006,000 (35.1%).
- Net loss of 298,000 reduced equity.
- New share issuances of 5,306,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-298.00K | -1.55% |
| Share Issuances | €5.31 Million | +27.57% |
| Other Changes | €-2.00K | -0.01% |
| Total Change | €- | 35.15% |
Book Value vs Market Value Analysis
This analysis compares Strategic Partners A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.16x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.28x to 0.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €267.20 | €76.00 | x |
| 2023-12-31 | €403.32 | €76.00 | x |
| 2024-12-31 | €461.45 | €76.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Strategic Partners A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-1.55%) is above the historical average (-2297.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -6708.84% | 0.00% | 0.00x | 18.55x | €-627.47 Million |
| 2023 | -182.90% | 0.00% | 0.00x | 1.36x | €-27.47 Million |
| 2024 | -1.55% | 0.00% | 0.00x | 1.22x | €-2.22 Million |
Industry Comparison
This section compares Strategic Partners A/S's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,432,955,421
- Average return on equity (ROE) among peers: -6.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Strategic Partners A/S (1TB0) | €18.06 Million | -6708.84% | 0.04x | $1.31 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |